10-K: Assure Holdings Corp. Navigates Strategic Shift with Asset Sale and Merger Plans

Assure Holdings Corp. divests its clinical operations and plans a merger with Danam Health, marking a significant strategic shift.

Summary

• Assure Holdings Corp. has undergone a major strategic shift, selling most of its clinical operations to National Neuromonitoring Services, LLC for $2.32 million in cash plus a potential earnout of up to $2.18 million.
• The company is also planning a merger with Danam Health, Inc., where former Assure equity holders are expected to own approximately 10% of the combined company.
• Assure's historical business involved providing Intraoperative Neurophysiological Monitoring (IONM) services, including both technical and professional components.
• The company has been exiting Managed Service Agreements (MSAs) and intends to terminate all remaining MSAs by the end of the third quarter of 2024.
• As of the filing date, Assure is providing IONM services in limited markets, primarily Arizona and Montana.
• The company has faced challenges including declining reimbursement rates for IONM services and has experienced operating losses of $26.1 million in 2023 and $30.1 million in 2022.
• Assure has also been subject to a civil investigation by the U.S. Department of Justice, which was settled for approximately $1 million.

Sentiment

Score: 3

Explanation: The document presents a company in a difficult financial situation undergoing a major strategic shift. While there are some positives like the asset sale and merger, the overall tone is negative due to the significant losses, debt, and compliance issues.

Positives

• The sale of clinical operations provides immediate cash and potential future earnings.
• The merger with Danam Health offers a new strategic direction for the company.
• Exiting MSAs allows Assure to retain more revenue from professional IONM services.
• The company has made investments in revenue cycle management to improve cash flow.
• Assure has a training program for Interoperative Neurophysiologists (INPs) to ensure a consistent level of service.

Negatives

• The company has experienced significant operating losses.
• There has been a decrease in commercial insurance reimbursement for IONM services.
• The company is dependent on a small group of third-party payors.
• There is a risk of not meeting financial covenants with Centurion Financial Trust.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company has not been in compliance with NASDAQ listing requirements.

Risks

• The merger with Danam may not be completed, and the company may have to pay a termination fee.
• The company may not be able to raise additional capital when needed.
• Assure faces significant competition from other healthcare providers.
• The company is subject to substantial government regulation and potential legal claims.
• Cybersecurity incidents could disrupt operations and result in loss of confidential information.
• The company's ability to use NOL carryforwards may be limited in connection with the merger.

Future Outlook

The company is focused on closing the merger with Danam and is pursuing arbitration opportunities related to uncollected accounts receivable. The company is also implementing cost-cutting measures to mitigate its going concern.

Management Comments

• Management believes that managed cases and remote neurology managed cases are important measures of the Company's operational performance because it is a consistent measurement to evaluate patient revenue streams.
• Management believes that the current reporting and trending software provides us with an accurate estimate of net patient service revenues.

Industry Context

The IONM market is highly fragmented with no dominant players, and is moving towards outsourced monitoring. The market is driven by growth in procedures related to an aging population, increase in prevalence of chronic disorders, adoption of IONM in new surgeries, and increased interest in risk mitigation. The market is also facing challenges including increasing costs of surgeries with IONM, payor payment denials, and a limited number of interoperative neurophysiologists.

Comparison to Industry Standards

• The document does not provide specific details on comparable companies or projects, but it does mention that the IONM market is highly fragmented with no dominant players.
• The document notes that some competitors are larger and have well-established relationships with physicians and third-party payors, and some are hospitals that provide IONM services within their facilities.
• The document also mentions bundled product companies as the largest IONM providers in the US, suggesting a competitive landscape where Assure is not a market leader.
• The document highlights that the eastern portions of the United States have higher utilization of IONM compared to the central and western portions, indicating regional variations in market adoption.

Management Changes

Legal Proceedings

• The company was subject to a civil investigation by the U.S. Department of Justice, which was settled for approximately $1 million.

Stakeholder Impact

• Shareholders will experience dilution due to the merger with Danam.
• Employees have been impacted by the sale of clinical operations and reduction in headcount.
• Customers may experience changes in service due to the strategic shift.
• Creditors may be impacted by the company's financial difficulties and potential default on debt obligations.

Next Steps

• The company is pursuing the closing of its transaction with Danam.
• The company intends to seek arbitration opportunities related to uncollected accounts receivable.
• The company will continue to implement cost-cutting measures.

Key Dates

Keywords

IONM, merger, Danam Health, asset sale, clinical operations, reimbursement, strategic review, tele-neurology, Managed Service Agreements, revenue cycle management